No Benefit Found in First Real Test of Renal Denervation

March 29, 2014 12:12 PM

17 0

SYMPLICITY HTN-3, the eagerly awaited first rigorous test of renal denervation, shows that the real effect of the novel blood-pressure-lowering technology is dramatically lower than earlier expectations, which had been fueled by data from previous uncontrolled trials. Results of SYMPLICITY HTN-3 were presented at the American College of Cardiology conference in Washington, DC, and published simultaneously in the New England Journal of Medicine.

The Medtronic-sponsored trial tested the effect of renal denervation in patients with resistant hypertension, defined as a sustained office systolic BP of at least 160 mm Hg confirmed by home BP and 24-hour ambulatory BP documentation of a systolic BP of at least 135 mm Hg. In all, 535 patients were...

Read more

To category page